Legend Biotech Q2 EPS $(0.05) Beats $(0.38) Estimate, Sales $186.52M Beat $126.59M Estimate
Portfolio Pulse from Benzinga Newsdesk
Legend Biotech (NASDAQ:LEGN) reported Q2 EPS of $(0.05), significantly beating the $(0.38) estimate. Sales were $186.52M, surpassing the $126.59M estimate. This represents a 91.23% improvement in EPS and a 154.36% increase in sales compared to the same period last year.
August 09, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend Biotech reported Q2 EPS of $(0.05), beating the $(0.38) estimate, and sales of $186.52M, surpassing the $126.59M estimate. This indicates a strong financial performance with a 91.23% improvement in EPS and a 154.36% increase in sales YoY.
The significant beat on both EPS and sales estimates, along with substantial year-over-year improvements, suggests strong financial health and positive market sentiment. This is likely to drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100